Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 309

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 309
---
 from government agencies and disease foundations. On October 1, 2020, DiamiR announced
that it received two grants from the National Institutes of Health (NIH) in the total amount of approximately $3.86 million. The
National Institute on Aging (NIA) awarded DiamiR approximately $3.36 million in a Commercialization Readiness Pilot (CRP) grant as
part of its Small Business Innovation Research (SBIR) program. The award builds upon earlier studies conducted by DiamiR in collaboration
with leading academic centers and continues to support development of CogniMIR, DiamiR’s lead diagnostic product
candidate for early detection and monitoring of mild cognitive impairment and AD. The second award of $498,572 was granted to DiamiR
by the National Institute for Neurological Disorders and Stroke (NINDS) for a project entitled “Circulating Organ-enriched microRNAs
as biomarkers of Rett Syndrome.”

DiamiR has received non-dilutive
funding to support its work. Below is a summary of DiamiR’s awards to date:

| * | indicates grants from the National Institutes of Health (NIH). |

NIH/NIA SBIR CRP Grant Number 2R44AG044860-07
09/01/2020 – 04/30/2024

Title: Brain-enriched microRNAs detectable in
plasma as biomarkers of Alzheimer’s disease

Analytical validation of CogniMIR
miRNA panel, and other studies supporting commercialization of the test within a CLIA/CAP laboratory.

NIH/NINDS SBIR Phase I Grant Number R43NS115212.
09/30/2020 – 03/30/2023

Title: Circulating organ-enriched microRNAs as
biomarkers of Rett syndrome.

NIH/NIA SBIR Phase IIB Grant Number 2R44AG044860-04
03/01/2017 – 08/28/2020

Title: Brain-enriched microRNAs detectable in
plasma as biomarkers of Alzheimer’s disease.

The main goal of this Phase IIB study is
to establish reliable pre-analytical protocol and analytical workflow for detection of brain-enriched microRNAs in plasma of AD patients
and control subjects.

NIH/NIA, Grant Number 3R44AG044860-06S1 (Admin.
Suppl